clinician
complex
task
attempt
identifi
infecti
diseas
aetiolog
particularli
critic
ill
patient
current
diagnost
practic
typic
detect
report
singl
pathogen
analysi
individu
patient
sampl
often
curtail
pathogen
detect
adopt
syndrom
approach
rapid
identif
infect
would
chang
current
clinic
diagnost
practic
also
provid
rapid
diagnost
tool
inexpens
suppli
evid
specif
infect
superinfect
particularli
paediatr
critic
ill
immunosuppress
patient
test
select
may
base
limit
inform
therefor
screen
mani
relev
pathogen
may
occur
simpli
request
refer
clinician
consequ
infecti
aetiolog
remain
unidentifi
delay
may
also
occur
refer
laboratori
requir
run
test
less
common
pathogen
greatli
increas
turnaround
time
result
patient
may
remain
extend
period
broadspectrum
therapi
pend
result
differ
test
associ
increas
drug
toxic
unwarr
select
pressur
antibiot
resist
cost
length
hospit
stay
therefor
great
need
simplifi
complex
workflow
pathogen
detect
identif
allow
rapid
initi
tailor
treatment
regimen
past
year
applic
qualit
quantit
nucleic
acid
detect
techniqu
dramat
alter
clinic
diagnost
practic
pcr
recent
realtim
pcr
revolutionis
diagnost
practic
clinic
microbiolog
laboratori
bankowski
anderson
cockeril
mackay
allow
rapid
pathogen
identif
combin
excel
sensit
specif
low
contamin
risk
speed
reduc
hand
time
eas
use
made
realtim
pcr
technolog
appeal
altern
convent
culturebas
immunoassaybas
test
method
often
time
consum
labour
intens
direct
result
introduct
realtim
pcr
clinic
microbiolog
turnaround
time
decreas
consider
obviou
benefit
bedsid
use
molecular
diagnost
proven
advantag
result
accur
result
overal
better
patient
care
outcom
molecular
diagnost
first
introduc
clinic
microbiolog
commerci
assay
avail
therefor
inhous
pcr
realtim
pcr
assay
develop
major
target
recent
year
expand
portfolio
commerci
assay
becom
avail
enabl
laboratori
extens
assay
develop
valid
practic
still
utilis
molecularbas
method
inhous
assay
develop
valid
accord
vitro
diagnost
ceivd
recommend
consid
ce
mark
iso
accredit
pcrbase
assay
qualit
quantit
meet
minimum
inform
public
quantit
realtim
pcr
experi
miqe
requir
detail
literatur
bustin
et
al
bustin
et
al
johnson
nour
nolan
huggett
bustin
taylor
wakem
dijkman
alsarraj
nguyen
compli
guidelin
outlin
develop
valid
diagnost
test
depend
nucleic
acid
amplif
detect
saunder
et
al
also
requir
use
standardis
materi
particip
extern
qualiti
control
programm
taqman
array
card
pcr
realtim
pcr
technolog
evolv
monoplex
multiplex
assay
mastermix
compris
sever
primerprob
set
multipl
pathogen
detect
array
technolog
revisit
monoplex
assay
utilis
simultan
singleplex
detect
mani
pathogen
full
spectrum
organ
thu
introduc
syndrom
rather
pathogenfocus
approach
diagnosi
taqman
array
card
tac
life
technolog
carlsbad
ca
formal
known
taqman
lowdens
array
tlda
microfluid
card
utilis
primer
probe
preload
lyophilis
onto
well
tac
platform
offer
singlepl
realtim
pcr
sampl
format
singl
target
test
avail
wellspod
includ
control
microfluid
technolog
distribut
sampl
individu
pcr
realtim
pcr
detect
take
place
within
analys
quantstudio
result
gener
less
h
process
individu
step
involv
set
card
schemat
outlin
figur
knowledg
tac
avail
realtim
pcr
platform
inher
abil
utilis
inhousevalid
pcr
assay
onto
singl
array
detect
quantifi
target
simultan
singl
specimen
simpl
robust
easili
transfer
applic
nucleic
acid
extract
ml
ad
mastermix
contain
enzym
buffer
nucleotid
taqman
fast
viru
mastermix
life
technolog
recommend
use
tac
other
wide
avail
reaction
volum
adjust
ml
nucleasefre
water
mix
transfer
singl
reservoirport
figur
eight
specimen
ad
reservoirsport
plate
centrifug
twice
min
g
seal
port
trim
scissor
load
realtim
pcr
viia
instrument
life
technolog
run
time
approxim
min
figur
practic
term
advantag
tac
numer
handl
time
train
requir
minim
substanti
improv
real
cost
clinic
diagnosi
data
interpret
straightforward
data
output
singl
userfriendli
file
lyophilis
primer
probe
onto
card
ensur
shelflif
year
refriger
allow
less
commonli
requir
card
store
readili
avail
loss
sensit
tac
also
ship
room
temperatur
ad
advantag
tac
abil
includ
confirmatori
assay
mani
pathogen
assay
design
detect
multipl
target
per
pathogen
enhanc
confid
diagnosi
figur
tac
format
disadvantag
group
report
reduc
sensit
compar
monoplex
assay
kodani
et
al
process
step
involv
run
tac
nucleic
acid
extractrtpcr
mastermix
ml
ad
portreservoir
specimen
centrifug
use
channel
mix
wellspod
contain
pair
lyophilis
primer
probe
specif
target
amplifi
realtim
pcr
eight
clinic
specimen
appli
plate
taqman
array
card
layout
pathogen
includ
sampl
sampl
one
intern
posit
control
bacteriophag
ic
two
human
dnarna
control
rnase
rna
includ
card
includ
addit
intern
posit
control
ie
phocin
distemp
viru
pdv
bacillu
thuringiensi
escherichia
coli
green
fluoresc
protein
gfp
ic
sever
pathogen
one
genet
target
includ
indic
number
usual
restrict
one
log
lower
limit
detect
lod
compar
monoplex
assay
kodani
mixsonhayden
drobeniuc
kamili
kodani
et
al
rachwal
et
al
howev
care
optimis
tac
test
multipl
target
pathogen
within
card
see
figur
use
effici
nucleic
acid
extract
method
particularli
sampl
blood
may
low
yield
organ
increas
extract
volum
well
nucleic
acid
input
volum
may
help
increas
sensit
suitabl
use
routin
diagnost
laboratori
diaz
et
al
addit
drawback
tac
technolog
includ
necess
screen
eight
sampl
parallel
avoid
wast
plu
limit
number
sampl
per
plate
maximum
eight
lack
autom
inaccess
card
downstream
analysi
pcr
product
array
requir
singl
anneal
temperatur
assay
card
therefor
individu
assay
must
optimis
work
effici
temperatur
requir
care
valid
process
assay
perform
optim
univers
condit
array
card
howev
valid
undertaken
addit
assay
panel
replac
exist
assay
new
improv
version
carri
without
need
extens
revalid
allow
flexibl
approach
report
drop
sensit
compar
monoplex
pcr
pertain
small
volum
analys
kodani
et
al
neg
impact
pathogen
clinic
relev
level
detect
lod
singl
copi
number
achiev
demonstr
inhousedevelop
respiratori
tac
figur
three
independ
influenza
b
realtim
array
assay
demonstr
detect
copi
per
reaction
use
synthet
plasmid
control
wwwgenscript
com
contain
three
target
sequenc
present
quantit
perform
tac
howev
attent
focus
upon
organ
respons
infect
detect
detect
answer
usual
suffici
adapt
tac
perform
quantit
possibl
clinic
need
function
multipl
organ
may
detect
singl
specimen
requir
care
interpret
clinician
determin
identifi
organ
respons
diseas
may
consid
commens
reli
clinic
judgement
howev
cycl
threshold
ct
valu
particular
organ
detect
tac
repres
rel
amount
organ
within
sampl
aid
interpret
good
exampl
illustr
point
multipl
infect
found
specimen
recent
process
gastro
tac
current
undergo
valid
network
public
health
england
phe
laboratori
figur
one
major
attract
array
technolog
abil
design
card
specif
syndrom
mind
exampl
describ
within
chapter
includ
infecti
respiratori
diseas
card
hepatitisjaundic
card
infecti
gastrointestin
diseas
card
central
nervou
system
cn
infect
card
sexual
transmit
infect
sti
card
see
figur
layout
card
develop
date
laboratori
possibl
includ
assay
antibiot
antivir
resist
relev
particular
organismsyndrom
exampl
carbapenamas
oseltamivir
resist
techniqu
also
use
surveil
pathogen
sought
routin
exampl
torovirus
kobuvirus
parvovirus
gastrointestin
diseas
array
card
use
outbreak
respons
exampl
respiratori
outbreak
wherebi
outbreak
specimen
rapidli
test
multipl
respiratori
pathogen
allow
rapid
initi
appropri
public
health
respons
implement
infect
control
precaut
prophylaxistreat
necessari
although
chapter
focus
tac
technolog
import
recognis
type
array
technolog
current
develop
diagnost
use
filmarray
technolog
biofir
diagnost
inc
salt
lake
citi
ut
pouchformat
array
incorpor
nucleic
acid
extract
multiplex
pcr
follow
nest
pcr
well
ml
volum
produc
result
within
h
pierc
elkan
leet
mcgowan
hodinka
popowitch
oneil
miller
singlesampl
format
make
technolog
inadequ
highthroughput
test
make
ideal
pointofcar
test
could
deploy
critic
situat
fieldbas
need
arm
forc
chapter
explor
tac
develop
aid
diagnosi
infect
individualis
process
accord
present
syndrom
base
predominantli
experi
fight
infecti
diseas
emerg
reemerg
pathogen
add
complex
import
appli
contemporari
knowledg
novel
technolog
aid
diagnosi
simplifi
complex
workflow
requir
pathogen
identif
gastro
tac
specimen
result
display
numer
pathogen
detect
broad
rang
ct
valu
miqe
ivd
guidelin
saunder
et
al
follow
design
optimis
assay
tac
take
consider
experiment
design
sampl
properti
nucleic
acid
extract
qualiti
assess
revers
transcript
rt
target
inform
primer
probe
design
realtim
pcr
protocol
optimis
valid
detail
data
analysi
exist
previous
valid
inhous
assay
taken
varieti
format
includ
monoplex
multiplex
realtim
pcr
differ
fluoresc
probe
quencher
initi
step
transform
assay
singl
monoplex
format
high
specif
sensit
use
ident
reaction
condit
chemistri
probe
report
fluorophor
quencher
although
assay
previous
extens
valid
chang
requir
transform
tac
assay
necessit
reoptimis
valid
opportun
provid
chanc
reevalu
assay
individu
perform
blast
analysi
wwwncbinlmgovblast
primer
probe
ensur
specif
utilis
recent
deposit
sequenc
genbank
databas
examin
primer
probe
melt
temperatur
whether
advers
primerprob
dimer
heterodim
interact
exist
use
oligoanalyz
wwwidtdna
com
requir
modif
instanc
primer
need
modifi
end
ad
targetmatch
extens
rais
approxim
ensur
uniform
amplif
across
differ
assay
singl
defin
temperatur
ideal
amplicon
length
nucleotid
accept
result
amplicon
nucleotid
length
huge
benefit
valid
tac
format
assay
incorpor
syndrom
tac
although
altern
may
consid
eas
use
interpret
probe
singl
fluoresc
dye
fam
minor
groov
binder
mgb
incorpor
nonfluoresc
quencher
end
favour
develop
tac
probe
proven
gener
better
precis
quantit
due
lower
background
signal
mgb
moieti
stabilis
hybridis
probe
effect
rais
melt
temperatur
increas
specif
mgb
probe
therefor
shorter
tradit
duallabel
probe
make
better
suit
applic
allel
discrimin
design
probe
region
high
content
genotyp
design
assay
detect
mutat
confer
drug
resist
major
assay
use
tradit
duallabel
quencher
transfer
mgb
format
minim
reoptimis
requir
inde
mani
case
shorter
mgb
probe
increas
sensit
effici
reaction
well
amplitud
fluoresc
signal
give
high
rise
sigmoid
amplif
curv
experi
design
mgb
probe
work
effect
probe
length
rang
nucleotid
taqman
fast
viru
mastermix
life
technolog
prefer
chemistri
tac
assay
therefor
initi
develop
work
must
ensur
exist
primer
probe
set
perform
adequ
use
chemistri
fast
ramp
cycl
time
exist
primer
probe
set
perform
adequ
modifi
new
assay
must
design
fast
viru
mastermix
amplifi
rna
dna
high
sensit
allow
mixandmatch
rtpcr
pcr
tac
ad
benefit
retain
high
sensit
even
presenc
rtpcr
inhibitor
often
found
blood
stool
typic
inhibitori
specimen
although
essenti
eas
use
chose
one
cutoff
threshold
valu
assay
develop
tac
figur
requir
care
assay
design
ensur
true
amplif
curv
high
rise
amplitud
cross
threshold
effect
assay
initi
development
stage
assay
optimis
utilis
realtim
platform
routin
use
inhous
assay
allow
eas
comparison
assay
sensit
specif
effici
fluoresc
intens
use
known
standard
patient
sampl
determin
rang
sampl
type
includ
plasma
stool
nasal
swab
bronchoalveolar
lavag
nasopharyng
aspir
npa
cn
fresh
biopsi
tissu
formalinfix
paraffinembed
specimen
may
includ
assay
optimis
extract
volum
also
optimis
increas
volum
benefici
low
level
pathogen
suspect
eg
earli
late
infect
intern
control
bacteriophag
bacillu
thuringiensi
cell
includ
extract
protocol
serv
process
control
rolf
et
al
next
step
transfer
assay
pcr
plate
format
use
fast
reaction
condit
see
figur
determin
sensit
specif
lod
assay
use
known
standard
patient
sampl
although
larger
volum
ml
use
pcr
plate
format
provid
good
indic
assay
perform
tac
ml
reaction
volum
due
proxim
fluoresc
detector
within
instrument
tac
spot
primer
probe
set
lyophilis
individu
pod
valid
procedur
must
undertaken
known
standard
virus
dilut
nucleic
acid
extract
unit
kingdom
nation
extern
qualiti
assess
neqa
qualiti
control
molecular
diagnost
qcmd
wwwqcmdorg
extern
qualiti
assur
panel
patient
specimen
deriv
differ
sampl
type
engin
synthet
plasmid
control
use
valid
kodani
winchel
employ
combin
allow
optim
assay
scrutini
provid
inform
lod
sensit
specif
reaction
inhibitor
differ
sampl
type
neqa
qcmd
panel
provid
good
indic
gener
tac
suffici
sensit
use
accredit
diagnost
servic
panel
engin
plasmid
control
serv
multipl
purpos
initi
determin
specif
assay
tac
lod
subsequ
determin
batch
variat
tac
develop
use
commerci
compani
genscript
wwwgenscriptcom
gener
panel
synthet
control
plasmid
contain
target
sequenc
nucleotid
side
primer
target
site
also
includ
combin
togeth
plasmid
panel
also
serv
qualitycheck
new
batch
tac
plate
checker
board
fashion
ensur
primer
probe
spot
correctli
assign
pod
extract
intern
control
rnase
p
gene
use
determin
sampl
qualiti
reaction
fail
control
reaction
outsid
predetermin
rang
specif
posit
control
assay
throughout
tac
also
enabl
user
determin
whether
suffici
centrifug
taken
place
mastermix
reach
pod
tac
emphasis
section
adopt
syndrom
approach
infecti
diseas
diagnos
mani
advantag
howev
also
requir
care
plan
input
clinician
diagnost
laboratori
team
design
syndrom
tac
involv
initi
decis
pathogen
consid
import
target
syndrom
identifi
frequent
andor
seriou
complic
advers
consequ
patient
syndrom
diagnosi
allow
rapid
turnaround
time
routin
diagnosi
also
rapid
respons
time
outbreak
situat
syndrom
approach
infecti
diseas
diagnosi
new
inhous
commerci
system
describ
use
techniqu
rang
multiplex
pcr
microarray
malditof
sequenc
combin
approach
first
syndrom
tac
infecti
diseas
describ
respiratori
array
card
develop
kodani
et
al
capabl
detect
target
virus
bacteria
plu
control
aim
diagnos
caus
acut
respiratori
infect
other
includ
expand
rang
organ
includ
caus
atyp
pneumonia
wider
rang
specif
organ
eg
influenza
subtyp
caus
infect
specif
patient
group
eg
receiv
extracorpor
membran
oxygen
ecmo
therapi
sever
respiratori
failur
due
suspect
infecti
aetiolog
see
figur
respiratoryecmo
card
layout
one
inher
advantag
tac
develop
process
abil
make
chang
improv
individu
assay
order
next
batch
plate
minimum
order
specimen
take
week
manufactur
current
respiratori
tac
eighth
version
dramat
improv
evolutionari
process
perform
commerci
avail
respiratori
zeptometrix
verif
panel
wwwzeptometrixcom
compar
cepheid
genexpert
flursv
test
biofir
filmarray
respiratori
panel
routin
multiplex
realtim
respiratori
assay
clearli
demonstr
tabl
moreov
perform
avail
qcmd
respiratori
pathogen
panel
wwwqcmdorg
last
year
excel
equal
case
superior
current
routin
molecular
realtim
respiratori
assay
improv
observ
tac
perform
develop
plate
correl
increas
analyt
sensit
individu
assay
reflect
fact
assay
eighth
version
respiratori
card
detect
approxim
copi
per
reaction
use
panel
synthet
plasmid
control
recent
comparison
routin
multiplex
assay
consecut
respiratori
specimen
demonstr
tac
perform
tabl
discrep
result
seen
specimen
late
ct
valu
low
viral
load
highlight
card
outperform
gold
standard
test
ie
sensit
rsv
adenoviru
modif
respiratori
tac
plate
tailor
ecmo
servic
adjust
assay
ecmo
card
highlight
bold
font
figur
evalu
laboratori
sinc
novemb
date
april
patient
specimen
process
ecmo
card
parallel
routin
investig
addit
confirm
routin
investig
find
ecmo
array
card
signific
benefici
impact
directli
influenc
clinic
manag
patient
notabl
infect
identifi
includ
mycoplasma
pneumonia
two
case
aspergillu
fumigatu
one
case
streptococcu
pyogen
two
case
dual
infect
influenza
mycobacterium
tuberculosi
one
case
streptococcu
pneumonia
six
case
long
recognis
mass
spectat
event
repres
huge
challeng
public
healthbring
possibl
import
infect
mass
transmiss
foodborn
infect
outbreak
transmiss
gastrointestin
infect
caus
major
issu
mass
spectat
event
identifi
caus
pathogen
problemat
repeat
studi
shown
overal
posit
routin
microscopi
cultur
stool
sampl
symptomat
individu
poor
compar
convent
pcr
select
refer
refer
list
demonstr
find
morgan
paillart
thompson
santo
rivera
stensvold
nielsen
need
comprehens
screen
assay
outbreak
set
routin
clinic
investig
therefor
recognis
latter
develop
use
number
set
liu
et
al
liu
et
al
pholwat
et
al
date
singl
screen
assay
avail
mass
event
set
assay
develop
tac
recent
develop
liu
et
al
simultan
detect
enteropathogen
constitut
signific
advanc
diagnost
gastrointestin
pathogen
card
allow
fast
accur
quantit
detect
broad
spectrum
enteropathogen
bacteria
virus
parasit
author
inhous
routin
multiplex
realtim
respiratori
pcr
assay
clark
et
al
b
influenza
sampl
dilut
viru
transport
medium
process
assay
increas
challeng
also
conclud
well
suit
surveil
clinic
purpos
followup
semin
studi
liu
et
al
assess
perform
tac
alongsid
two
molecular
platform
pcr
luminex
multiplex
realtim
pcr
inhous
compar
method
bacteri
cultur
elisa
pcr
use
specimen
molecular
quantit
approach
clearli
superior
laboratori
particip
studi
taqman
array
card
platform
view
favour
complet
syndrom
screen
implement
procur
simpl
risk
contamin
scant
quantif
robust
develop
gastrointestin
tac
incorpor
assay
describ
liu
et
al
expand
addit
assay
eg
enteroviru
noroviru
group
parechoviru
hepat
e
virus
outlin
figur
valid
plate
current
underway
network
region
laboratori
within
phe
data
gener
sampl
process
far
extrem
encourag
clearli
illustr
perform
obtain
recent
noroviru
qcmd
tabl
clostridium
difficil
qcmd
tabl
panel
rachwal
colleagu
publish
studi
describ
array
detect
biothreat
organ
rachwal
et
al
includ
bacillu
anthraci
francisella
tularensi
yersinia
pesti
burkholderia
mallei
burkholderia
pseudomallei
initi
paper
kodani
et
al
author
point
array
system
around
less
sensit
singleplex
rtpcr
assay
perform
alongsid
factor
born
mind
consid
clinic
applic
assay
sinc
relev
low
ct
valu
result
alway
point
content
issu
new
molecular
diagnost
howev
outlin
respiratori
tac
strive
improv
assay
card
develop
ensur
sublim
assay
exquisit
analyt
sensit
migrat
finalis
valid
diagnost
card
mitig
address
point
addit
tac
develop
within
laboratori
like
respiratori
gastro
tac
shown
figur
jaundic
tac
design
incorpor
assay
consid
import
caus
complic
jaundic
patient
assay
jaundic
tac
current
includ
hepat
virus
ag
hcv
genotyp
erythroviru
sen
viru
senv
dengu
viru
panadenoviru
polyomavirus
bk
jc
herp
virus
toxoplasma
gondii
tuberculosi
complex
chlamydophila
psittaci
intern
control
figur
similar
tac
also
develop
center
diseas
control
prevent
cdc
atlanta
limit
hepat
virus
kodani
et
al
includ
addit
pathogen
allow
rapid
comprehens
diagnosi
without
requir
multipl
blood
biopsi
sampl
sought
patient
also
remov
limit
possibl
miss
complic
infect
initi
diagnosi
made
anoth
area
tac
appli
diagnosi
infect
immunocompromis
patient
number
transplant
per
year
continu
rise
place
increas
demand
clinic
care
team
therefor
also
diagnost
laboratori
despit
technic
innov
morbid
mortal
rate
improv
past
year
mainli
due
infect
cardiovascular
diseas
malign
signific
advanc
earli
diagnosi
infect
benefici
impact
morbid
mortal
rate
therefor
continu
focu
current
diagnost
algorithm
improv
modif
jaundic
tac
replac
hcv
genotyp
assay
addit
assay
care
select
includ
consid
problemat
transplant
immunocompromis
patient
gener
first
comprehens
diagnost
algorithm
infect
set
figur
assay
transplant
tac
includ
herp
virus
human
polyomavirus
bkjcwuki
mc
human
papillomavirus
pan
hpv
mrna
genotyp
erythroviru
panadenoviru
hepat
virus
ag
sen
v
gondii
tuberculosi
complex
fungal
speci
aspergillu
candida
speci
mani
tac
develop
eg
cn
infect
figur
sti
unit
kingdom
elsewher
versatil
approach
adapt
highlight
fact
readili
recruit
use
mixandmatch
style
depend
local
outbreak
requir
furthermor
due
eas
use
consid
parachut
technolog
fast
track
need
aris
resourc
poor
set
chapter
outlin
develop
use
tac
clinic
diagnost
laboratori
number
differ
tac
avail
continu
expand
versatil
explain
clinic
intervent
tool
offer
mani
possibl
local
use
tac
assay
provid
rapid
diagnosi
serious
ill
patient
requir
ecmo
also
instrument
identifi
possibl
caus
agent
recur
rhabdomyolysi
young
child
hsv
type
pneumonia
immunocompet
patient
case
bk
virusinduc
pneumonia
immunocompromis
patient
would
otherwis
remain
undiagnos
addit
real
potenti
use
tac
outbreak
situat
recognis
abil
identifi
pneumonia
caus
agent
outbreak
among
univers
student
waller
et
al
outbreak
tac
exhibit
sensit
specif
compar
multiplex
realtim
pcr
allow
outbreak
quickli
recognis
appropri
manag
syndrom
approach
offer
mani
advantag
monoplex
target
one
assay
without
limit
concommit
loss
sensit
use
rel
small
amount
nucleic
acid
extract
consid
asid
tac
herald
step
forward
develop
versatil
molecular
assay
diagnosi
infecti
diseas
